Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Lorant, Leopold"'
Autor:
Johan Vingerhoets, Ilse Van Dromme, Wilbert van Duijnhoven, David Anderson, Sandra De Meyer, Lorant Leopold
Publikováno v:
Antiviral Therapy. 28:135965352311742
Background Pimodivir is a first-in-class polymerase basic protein 2 (PB2) subunit inhibitor of the influenza A polymerase complex. The randomized double-blinded placebo-controlled phase 2b TOPAZ study demonstrated antiviral activity and safety of twi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::358eb279096a3d2da98463049b058e4c
https://doi.org/10.1177/13596535231174273
https://doi.org/10.1177/13596535231174273
Autor:
Wilbert, van Duijnhoven, Ilse, Van Dromme, Steven, Haesendonckx, James, Witek, Lorant, Leopold
Publikováno v:
Contemporary Clinical Trials. 123:106952
Currently, no single best primary endpoint exists for measuring the efficacy of treatments in seriously ill patients with respiratory infections, such as influenza, who require hospitalization. The Hospital Recovery Scale is an ordinal endpoint used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95f98deaa25a7e57b5c86b451671a7bc
https://doi.org/10.1016/j.cct.2022.106952
https://doi.org/10.1016/j.cct.2022.106952
Autor:
Antoni Torres, Lorant Leopold, Sofie Deleu, John Wilburn, Anna Christine Nilsson, Brian J. O'Neil, Stefaan Rossenu, Marie-Charlotte Hallouin-Bernard, Wilbert van Duijnhoven, Teddy Kosoglou, Ilse Van Dromme, Michael G. Ison, David E. Anderson, Johan Vingerhoets
Publikováno v:
The Journal of infectious diseases. 226(1)
Background Both the elderly and individuals with comorbidities are at increased risk of developing influenza-related complications. Novel influenza antivirals are required, given limitations of current drugs (eg, resistance emergence and poor efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff75e0fcd764a650f6a5616c1ce576bf
https://pubmed.ncbi.nlm.nih.gov/32604406
https://pubmed.ncbi.nlm.nih.gov/32604406
Autor:
Sofie Deleu, Kurt Spittaels, Thomas N. Kakuda, Lorant Leopold, Vera Hillewaert, Jurgen Vercauteren, Amy Lwin, Richard M. W. Hoetelmans
Publikováno v:
British Journal of Clinical Pharmacology. 84:2663-2672
AIMS: The aim of this study was to evaluate the drug–drug interaction between pimodivir, a novel, non‐nucleoside polymerase basic protein 2 (PB2) subunit inhibitor of the influenza A virus polymerase complex, and oseltamivir, to assess the feasib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3564656db8be8ae61d03fffc94c97ea9
https://doi.org/10.1111/bcp.13733
https://doi.org/10.1111/bcp.13733
Autor:
Johan Vingerhoets, Ramon Polo, Ying Jiang, Mohammed Asmal, Tara L. Kieffer, Sarah Robertson, Jose M Trevejo, Lorant Leopold
Publikováno v:
Antiviral Therapy. 23:335-344
Background Pimodivir (formerly JNJ-63623872) is a novel, non-nucleoside polymerase complex inhibitor with in vitro activity against influenza A virus, including pandemic 2009 H1N1, H7N9, H5N1 strains as well as neuraminidase- and amantadine-resistant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c70dd4f90aa23e92d96535fdf5de3c8a
https://doi.org/10.3851/imp3212
https://doi.org/10.3851/imp3212
Autor:
Lorant Leopold, Lanno R, Robert W. Finberg, Kauffman Rs, Johan Vingerhoets, Roman Fleischhackl, van Duijnhoven W, Kosoglou T, David E. Anderson
Publikováno v:
The Journal of infectious diseases. 219(7)
BACKGROUND Pimodivir, a first-in-class inhibitor of influenza virus polymerase basic protein 2, is being developed for hospitalized and high-risk patients with influenza A. METHODS In this double-blinded phase 2b study, adults with acute uncomplicate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a31a1008144b31e200c6b11044432e40
https://pubmed.ncbi.nlm.nih.gov/30428060
https://pubmed.ncbi.nlm.nih.gov/30428060
Autor:
Frank Tomaka, Maarten Timmers, Vera Hillewaert, Richard M. W. Hoetelmans, Thomas N. Kakuda, Lorant Leopold, Tom Van De Casteele
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 52:805-816
UNLABELLED Once-daily darunavir/ritonavir (800/100 mg), plus other antiretrovirals, is recommended for HIV-1-infected patients. Low therapy adherence is linked with poor outcomes. Pill burden can impact adherence. An 800-mg darunavir tablet would red
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eccb199b1a7ef5e1571e85f8c2624816
https://doi.org/10.5414/cp202066
https://doi.org/10.5414/cp202066
Autor:
Steven Nijs, Thomas N. Kakuda, Veerle Vyncke, Monika Peeters, Goedele De Smedt, Richard M. W. Hoetelmans, Lorant Leopold, Ruud Leemans, Cindy Berckmans, Rodica Van Solingen-Ristea
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 51:725-736
Objectives Three studies were conducted to assess the pharmacokinetics, methods of administration and ease of swallowability of etravirine tablets. Methods Two randomized studies in healthy adults investigated the single-dose pharmacokinetics of etra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec77d2fbc7abdbf4745ff0ec4c59ca00
https://doi.org/10.5414/cp201770
https://doi.org/10.5414/cp201770
Autor:
Thomas N, Kakuda, Lorant, Leopold, Steven, Nijs, Ann, Vandevoorde, Herta M, Crauwels, Kirk M, Bertelsen, Marita, Stevens, James, Witek, Yvon, van Delft, Frank, Tomaka, Richard M W, Hoetelmans
Publikováno v:
Journal of clinical pharmacology. 54(5)
Coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) may require treatment with an HIV non-nucleoside reverse transcriptase inhibitor (NNRTI), for example, rilpivirine or etravirine, and an HCV direct-acting antiviral drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fd8120da7f80e1bf77606d5f93b42f88
https://pubmed.ncbi.nlm.nih.gov/25975423
https://pubmed.ncbi.nlm.nih.gov/25975423